Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Analysts at GlobalData think that faricimab and another Roche-developed product will be the main derivers of the market in the coming years. The companion product – Susvimo – is an implantable ...

The actor who plays a villain on the ‘Yellowstone’ prequel series explains how his character’s “diabolical” mission led to a “dissent into madness” for the man who would never die ...

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March 2025. The chart below provides highlights of key monograph updates ...

Reproxalap, a first-in-class small-molecule modulator of reactive aldehyde species (RASP), is under review for the treatment of the signs and symptoms of dry eye disease. It works by covalently ...

European shares fell on Wednesday, weighed by losses in healthcare stocks, as investors awaited tariff plans from U.S. President Donald Trump that some fear could slow global growth and boost ...